Bradley Canino
Stock Analyst at Guggenheim
(3.86)
# 1,821
Out of 4,382 analysts
292
Total ratings
39.3%
Success rate
6.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintained: Buy | $165 | $88.28 | +86.91% | 14 | Jun 3, 2026 | |
| SMMT Summit Therapeutics | Maintained: Buy | $40 | $14.77 | +170.82% | 15 | Jun 1, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $38 → $35 | $10.31 | +239.48% | 5 | Jun 1, 2026 | |
| NUVL Nuvalent | Maintained: Buy | $151 | $90.95 | +66.03% | 15 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Buy | $42 | $20.00 | +110.00% | 2 | May 26, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $22 → $26 | $13.52 | +92.31% | 18 | May 25, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $68 → $58 | $13.35 | +334.46% | 9 | May 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $7.50 | +140.00% | 9 | May 4, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $125 | $74.13 | +68.62% | 20 | Apr 30, 2026 | |
| CBIO Crescent Biopharma | Maintained: Buy | $35 | $18.00 | +94.44% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $40 | $21.07 | +89.84% | 4 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $26.64 | +102.70% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $13.51 | +122.06% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $53.72 | +67.54% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $17.34 | +96.08% | 16 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $3.85 | +81.82% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.97 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $8.74 | - | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $1.78 | +180.90% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $3.66 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1.5 | $1.54 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $63 → $51 | $7.42 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $3.92 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $44.30 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 | $3.33 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $5.58 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $52.70 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $24.04 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $22.90 | n/a | 1 | Jul 8, 2020 |
Celcuity
Jun 3, 2026
Maintained: Buy
Price Target: $165
Current: $88.28
Upside: +86.91%
Summit Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $40
Current: $14.77
Upside: +170.82%
Olema Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $38 → $35
Current: $10.31
Upside: +239.48%
Nuvalent
Jun 1, 2026
Maintained: Buy
Price Target: $151
Current: $90.95
Upside: +66.03%
Bicara Therapeutics
May 26, 2026
Maintained: Buy
Price Target: $42
Current: $20.00
Upside: +110.00%
Relay Therapeutics
May 25, 2026
Maintained: Buy
Price Target: $22 → $26
Current: $13.52
Upside: +92.31%
Janux Therapeutics
May 7, 2026
Reiterated: Buy
Price Target: $68 → $58
Current: $13.35
Upside: +334.46%
ORIC Pharmaceuticals
May 4, 2026
Reiterated: Buy
Price Target: $18
Current: $7.50
Upside: +140.00%
Kymera Therapeutics
Apr 30, 2026
Reiterated: Buy
Price Target: $125
Current: $74.13
Upside: +68.62%
Crescent Biopharma
Apr 29, 2026
Maintained: Buy
Price Target: $35
Current: $18.00
Upside: +94.44%
Apr 29, 2026
Rated: Buy
Price Target: $40
Current: $21.07
Upside: +89.84%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $26.64
Upside: +102.70%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $13.51
Upside: +122.06%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $53.72
Upside: +67.54%
Feb 26, 2026
Reiterated: Buy
Price Target: $34
Current: $17.34
Upside: +96.08%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $3.85
Upside: +81.82%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.97
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $8.74
Upside: -
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $1.78
Upside: +180.90%
Mar 27, 2025
Maintained: Buy
Price Target: $9
Current: $3.66
Upside: n/a
Mar 7, 2025
Maintained: Hold
Price Target: $3 → $1.5
Current: $1.54
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $63 → $51
Current: $7.42
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $3.92
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $44.30
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $68
Current: $3.33
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $5.58
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $52.70
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $24.04
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $22.90
Upside: n/a